Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A

The FDA-approved EGFR/HER2 inhibitor varlitinib inhibits tumor growth and is used in cancer treatment. However, the neuroinflammatory response associated with EGFR/HER2 and its underlying mechanism have not been elucidated. This study evaluates the impact of varlitinib on LPS- and tau-mediated neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jieun, Kim, Su-Jin, Jeong, Ha-Ram, Park, Jin-Hee, Moon, Minho, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632417/
https://www.ncbi.nlm.nih.gov/pubmed/36341365
http://dx.doi.org/10.3389/fimmu.2022.903309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632417/
https://www.ncbi.nlm.nih.gov/pubmed/36341365
http://dx.doi.org/10.3389/fimmu.2022.903309

Ejemplares similares